Search

Your search keyword '"Dhamne, Chetan"' showing total 233 results

Search Constraints

Start Over You searched for: Author "Dhamne, Chetan" Remove constraint Author: "Dhamne, Chetan"
233 results on '"Dhamne, Chetan"'

Search Results

2. Pediatric Acute Leukemias

3. Pediatric Hodgkin Lymphoma

5. Treating relapsed B cell-precursor ALL in children with a setting-adapted mitoxantrone-based intensive chemotherapy protocol (TMH rALL-18 PROTOCOL) — experience from Tata Memorial Hospital, India

6. Epilepsia Partialis Continua as a Sequelae of Measles Infection in Children With Hematolymphoid Malignancies

9. Outcomes of COVID-19 and risk factors in patients with cancer

13. A novel amplification of JAK2 in a case of relapsed pediatric B-ALL

14. KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1

15. 15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy (anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic leukemia/lymphoma: Real‐world applicability and challenges

19. P360: MEASURABLE/MINIMAL RESIDUAL DISEASE (MRD) STATUS IS THE MOST RELEVANT INDICATOR OF CLINICAL OUTCOME IN MIXED PHENOTYPIC ACUTE LEUKEMIAS (MPAL)

20. NARASIMHA: Novel Assay based on Targeted RNA Sequencing to Identify ChiMeric Gene Fusions in Hematological Malignancies

21. Treatment and follow‐up of children with chronic myeloid leukaemia in chronic phase (CML‐CP) in the tyrosine kinase inhibitor (TKI) era—Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort.

24. Clinicopathological and treatment response characteristics of updated rhabdomyosarcoma histomolecular subtypes: An Asian population‐based study

26. 15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy (anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic leukemia/lymphoma: Real‐world applicability and challenges

27. Prospective collaborative study for pulse dexamethasone and lenalidomide in relapsed / refractory langerhans cell histiocytosis (LENDEX-LCH study): INPHOG-HIST-19-03 (CTRI/2020/07/026937)

28. Comprehensive database for delivery and monitoring of holistic pediatric cancer care - Experience of impact foundation over a decade

29. Pediatric cancer‐associated thrombosis: Analysis from a tertiary care cancer center in India

30. 2. Clinical, cytogenetic and genomic profiling of B-Other Acute Lymphoblastic Leukemia: An Indian cohort study

37. COVID-19 in children with cancer and continuation of cancer-directed therapy during the infection- A tertiary care center experience from India

38. Clinical outcomes and prognostic factors in children with B-cell lymphoblastic lymphoma (LBL) treated according to on modified BFM-90 protocol: Experience from a Tertiary cancer care center in India

39. Clinicopathologic Profile and Treatment Outcomes of Children With Diffuse Large B-cell Lymphomas (DLBCL)

40. Predictors and Treatment Outcomes of Pediatric Osteosarcoma in Diverse Socioeconomic Backgrounds in Southeast Asia: A Retrospective Multicenter Study

41. Imatinib-induced retroperitoneal fibrosis in a child with chronic myeloid leukemia: a case report

43. Treatment and long-term follow-up of children with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Experience from the Tata Memorial Hospital pediatric CML cohort over 2 decades

45. Haploidentical stem cell transplantation of paediatric hematolymphoid conditions - An experience from a public sector hospital

46. Clinical features and outcome of posterior reversible encephalopathy syndrome (PRES) in children with hematolymphoid malignancies

47. Outcomes of COVID-19 and risk factors in patients with cancer - a cohort study

Catalog

Books, media, physical & digital resources